The position of bevacizumab in the treatment of colorectal cancer
06/2018
MUDr. Igor Richter, Ph.D.1,2, doc. MUDr. Josef Dvořák, Ph.D.2, MUDr. Jiří Bartoš, MBA1
1) Onkologické oddělení Krajské nemocnice Liberec
2) Onkologická klinika 1. LF UK a Thomayerovy nemocnice, Praha
SUMMARY
Metastatic colorectal cancer is one of the day-to-day diagnoses of oncology centers. In addition to chemotherapy, we also have the opportunity to receive targeted treatment. Bevacizumab is a monoclonal antibody against vascular endothelial factor and we have more than ten years of experience with it. The review article evaluates the current status of bevacizumab in the treatment of metastatic colorectal cancer, where its position in the treatment algorithm of the disease has recently been clarified without a clear predictive factor. Finally, there is a case report of the patient who responds well to chemotherapy in combination with bevacizumab in the first line, despite left-hand localization and the non-mutated RAS gene.
KEY WORDS
colorectal carcinoma, metastasis, angiogenesis, bevacizumab, chemotherapy, targeted therapy
The full article is only available to subscribers
Become a regular subscriber to our Oncological Review...